Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide

Journal of Clinical Oncology

Volumn 21, Issue 18, 2003, Pages 3462-3468

  Papaldo, Paola ^a   Lopez, Massimo ^a   Cortesi, Enrico ^a   Cammilluzzi, Eugenio ^a   Antimi, Mauro ^a   Terzoli, Edmondo ^a   Lepidini, Giuseppe ^a   Vici, Patrizia ^a   Barone, Carlo ^a   Ferretti, Gianluigi ^a   Di Cosimo, Serena ^a   Nisticò, Cecilia ^a   Carlini, Paolo ^a   Conti, Francesca ^a   Di Lauro, Luigi ^a   Botti, Claudio ^a   Vitucci, Carlo ^a   Fabi, Alessandra ^a   Giannarelli, Diana ^a   Marolla, Paolo ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LONIDAMINE; ANTINEOPLASTIC AGENT; INDAZOLE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME; ADULT; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FILGRASTIM; FOLLOW-UP STUDIES; HUMANS; INDAZOLES; MIDDLE AGED; SURVIVAL RATE;

EID: 0142058027     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.034     Document Type: Article

References (39)

1. Paggi MG, Zupi G, Fanciulli M, et al: Effect of lonidamine on the utilization of 14C-labeled glucose by human astrocytoma cells. Exp Mol Pathol 47:154-165, 1987
2. Floridi A, Delpino A, Nista A, et al: Effect of lonidamine on protein synthesis in neoplastic cells. Exp Mol Pathol 42:293-305, 1985
3. Costantini P, Jacotot E, Decaudin D, et al: Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 92:1042-1053, 2000
4. Pulselli R, Amadio L, Fanciulli M, et al: Effect of lonidamine on the mitochondrial potential in situ in Ehrlich ascites tumor cells. Anticancer Res 16:419-423, 1996
5. Belzacq AS, El Hamel C, Vieira HL, et al: Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 20:7579-7587, 2001
6. Sordet O, Rebe C, Leroy I, et al: Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood 97:3931-3940, 2001
7. Ravagnan L, Marzo I, Costantini P, et al: Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 18:2537-2546, 1999
8. Malorni W, Meschini S, Matarrese P, et al: The cytoskeleton as a subcellular target of the antineoplastic drug lonidamine. Anticancer Res 12:2037-2045, 1992
9. Mardor Y, Kaplan O, Sterin M, et al: Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy. Cancer Res 60:5179-5186, 2000
10. Dell'Antone P, Piergallini L: The antineoplastic drug lonidamine interferes with the acidification mechanism of cell organelles. Biochim Biophys Acta 1358:46-52, 1997
11. Dell'Antone P, Bragadin M, Piergallini L: Lonidamine cytotoxicity: Involvement of the lysosomal compartment. J Int Med Res 28:269-276, 2000
12. Ben-Yoseph O, Lyons JC, Song CW, et al: Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification. J Neurooncol 36:149-157, 1998
13. Floridi A, Gambacurta A, Bagnato A, et al: Modulation of adriamycin uptake by lonidamine in Ehrlich ascites tumor cells. Exp Mol Pathol 49:421-431, 1988
14. Floridi A, Bianchi C, Bagnato A, et al: Lonidamine-induced outer membrane permeability and susceptibility of mitochondria to inhibition by adriamycin. Anticancer Res 7:1149-1152, 1987
15. Bagnato A, Bianchi C, Caputo A, et al: Enhancing effect of lonidamine on the inhibition of mitochondrial respiration by adriamycin. Anticancer Res 7:799-802, 1987
16. Zupi G, Molinari A, D'Agnano I, et al: Adriamycin resistance modulation induced by lonidamine in human breast cancer cells. Anticancer Res 15:2469-2477, 1995
17. Fanciulli M, Valentini A, Bruno T, et al: Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells. Oncol Res 8:111-120, 1996
18. Di Cosimo S, Ferretti G, Papaldo P, et al: Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumours. Drugs of Today 39:157-174, 2003
19. Tomirotti M, Bernardo G, Epifani C, et al: Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients. Int J Oncol 3:213-217, 1993
20. Dogliotti L, Berruti A, Buniva T, et al: Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: Results from a multicenter prospective randomized trial. J Clin Oncol 14:1165-1172, 1996
21. Calabresi F, Di Lauro L, Marolla P, et al: Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: A multicentric randomized clinical study. Semin Oncol 18:66-72, 1991 (suppl 4)
22. Carmo-Pereira J, Costa FO, Miles DW, et al: High-dose epirubicin as primari chemotherapy in advanced breast carcinoma: A phase II study. Cancer Chemother Pharmacol 27:394-396, 1991
23. Marschner N, Nagel GA, Beyer JH, et al: High-dose epirubicin in combination with cyclophosphamide in advanced breast cancer: Final results of a dose-finding study and phase II trial. Onkologie 13:272-278, 1990
24. Piccart M, van der Schueren E, Bruningx P, et al: High-dose intensity chemotherapy with epiadiamycin, cyclophosphamide and r-met HuG-CSF in breast cancer patients. Eur J Cancer 27:S56, 1991 (abstr 308)
25. Martin M, Lluch A, Gillem V, et al: High-dose epirubicin plus cyclophosphamide as primari chemotherpapy in stage III a/b breast cancer. Eur J Cancer 27:S58, 1991 (abstr 323)
26. Amadori D, Frassineti GL, De Matteis A, et al: Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial. Breast Cancer Res Treat: 49:209-217, 1998
27. Harris AL, Hochhauser D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31:205-213, 1992
28. Berruti A, Bitossi R, Gorzegno G, et al: Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: Final results of a phase III study with a factorial cesign. J Clin Oncol 20:4150-4159, 2002
29. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602-611, 2001
30. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998
31. Piccart MJ, Di Leo A, Beauduin M, et al: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103-3110, 2001
32. Launchbury AP, Habboubi N: Epirubicin and doxorubicin: A comparison of their characteristic, therapeutic activity and toxicity. Cancer Treat Rev 19:187-228, 1993
33. Arriagada R, Spielmann M, Koscielny S, et al: Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen. Ann Oncol 13:1378-1386, 2002
34. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
35. Fisher B, Dignam J, Mamounas EP, et al: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14:1982-1992, 1996
36. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial-The International Collaborative Cancer Group. J Clin Oncol 14:35-45, 1996
37. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134-2140, 1991
38. Hutchins L, Green S, Ravdin P, et al: CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT0102. Proc Am Soc Clin Oncol 17:1a, 1998 (abstr)
39. Tormey DC, Gray R, Abeloff MD, et al: Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol 10:1848-1856, 1992